The IPO Buzz
IPO Calendar
Last Week's IPO Traffic
2014 Pricings
Last 100 IPOs
Last 12 Months
IPOs by Managers
By Industry
Secondary Offerings
IPO Pipeline
SCOOP Ratings
IPOs Recently Filed
IPOs by Managers
By Industry
Secondary Offerings
SCOOP Track Record From 2000 to Present
IPO Traffic by Week
IPO Index
Dance Biopharm 
General Information
Business: We are a biopharmaceutical company focused on the development of inhaled insulin products for the treatment of diabetes. Our lead product candidate, Dance 501, is a drug/device combination product designed to deliver a high purity liquid insulin formulation through a small handheld electronic inhaler to reduce or eliminate the need for daily injections. We recently completed a Phase 2, randomized, active controlled clinical trial investigating three dose levels of inhaled insulin in adult patients with type 2 diabetes and we plan to initiate a global Phase 3 clinical trial in early 2015.
Employees: 16 Founded: 2009
Contact Information
Address: 150 North Hill Drive, Suite 24, Brisbane, CA 94005 , US
Phone: 415-369-9415
Web Address:
View Prospectus: Dance Biopharm
Financial Information
Market Cap:
Revenues: $ 0.0 mil (last 12 months)
Net Income: $ -8.5 mil (last 12 months)
IPO Profile
Symbol: DNCE
Shares (millions):
Price Range: $ - $
Est.$ Volume $ 75.0 mil
Manager / Joint Managers Wells Fargo Securities/ Stifel
Co Managers Oppenheimer/ Roth Capital Partners
Expected to Trade
Status Withdrawn
SCOOP RATING Available only to Subscribers
RATING CHANGE Available only to Subscribers

© 2014 All rights reserved.